GlassScriptPhysician profile
Natalee Neikirk
NPI 1225498314
$8,099.96
in general payments reported to CMS, 2019-2025
55 companies · $914 in 2025
The $914 reported for 2025 was more than what 85% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,548 · 2022: $1,875 · 2023: $1,845 · 2024: $1,917 · 2025: $914.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,616 · Education: $60.30.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,616.37 |
| Education | $60.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $926.70 | 2021-2025 | |
| Amgen INC. | $718.65 | 2021-2024 | Lumakras, Evenity, Prolia |
| Merck Sharp & Dohme LLC | $668.37 | 2021-2025 | Keytruda, Welireg, Lynparza |
| Astrazeneca Pharmaceuticals LP | $610.29 | 2021-2025 | Tagrisso, Enhertu, Calquence |
| Pfizer INC. | $475.24 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $455.72 | 2021-2024 | Opdivo, Opdualag |
| Genmab U.S., INC. | $294.04 | 2023-2025 | Tivdak, Epkinly |
| Daiichi Sankyo INC. | $287.84 | 2021-2025 | Enhertu, Injectafer |
| Takeda Pharmaceuticals U.S.A., INC. | $282.80 | 2021-2025 | Fruzaqla, Iclusig, Ninlaro |
| Janssen Biotech, INC. | $270.27 | 2021-2025 | Darzalex, Imbruvica, Rybrevant |
| Astellas Pharma US INC | $205.36 | 2021-2025 | Xtandi, Xospata |
| Celgene Corporation | $176.92 | 2022-2025 | Reblozyl, Pomalyst |
| Array Biopharma INC | $158.82 | 2021-2025 | Lorbrena, Mektovi, Braftovi |
| Regeneron Healthcare Solutions, INC. | $158.81 | 2021-2025 | Libtayo |
| Gilead Sciences, INC. | $152.21 | 2022-2025 | Trodelvy |
Show all 55 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacosmos Therapeutics INC. | $140.99 | 2023-2025 | Monoferric, Cosela |
| Incyte Corporation | $136.56 | 2021-2024 | Jakafi, Pemazyre, Monjuvi |
| Shield Therapeutics INC | $135.41 | 2024 | |
| Coherus Oncology, INC. | $125.25 | 2021-2025 | Loqtorzi |
| Genentech USA, INC. | $124.70 | 2022-2025 | Tecentriq, Phesgo, Itovebi |
| Rigel Pharmaceuticals, INC. | $115.89 | 2021-2024 | Rezlidhia, Tavalisse |
| Kyowa Kirin, INC. | $107.71 | 2021-2023 | Poteligeo |
| Abbvie INC. | $101.03 | 2022-2024 | |
| Genzyme Corporation | $99.09 | 2021-2023 | |
| Eisai INC. | $89.99 | 2022-2025 | |
| Jazz Pharmaceuticals INC. | $84.78 | 2021-2025 | |
| Seagen INC. | $83.64 | 2021-2023 | Adcetris |
| Ipsen Biopharmaceuticals, INC | $66.38 | 2021-2023 | Tazverik |
| Lilly USA, LLC | $65.90 | 2021-2024 | Jaypirca, Retevmo, Verzenio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.20 | 2022-2023 | Gilotrif |
| Glaxosmithkline, LLC. | $51.87 | 2023-2024 | Jemperli, Zejula |
| Alexion Pharmaceuticals, INC. | $49.09 | 2022-2024 | Ultomiris |
| Blueprint Medicines Corporation | $47.86 | 2023 | Ayvakit |
| Puma Biotechnology, INC. | $47.78 | 2022-2025 | |
| Beigene USA, INC. | $46.74 | 2021-2024 | Brukinsa |
| Emd Serono, INC. | $46.65 | 2021-2024 | |
| Stemline Therapeutics INC. | $42.68 | 2023 | Orserdu |
| Bayer Healthcare Pharmaceuticals INC. | $35.17 | 2021-2025 | |
| Collegium Pharmaceutical, INC. | $30.36 | 2021 | |
| Morphosys, US INC. | $30.08 | 2022-2023 | Monjuvi |
| Karyopharm Therapeutics INC. | $30.05 | 2021-2022 | |
| Sobi, INC | $29.42 | 2023 | |
| Dova Pharmaceuticals | $24.18 | 2021 | |
| Taiho Oncology, INC. | $23.94 | 2025 | |
| Celltrion USA INC. | $22.78 | 2025 | Vegzelma |
| Agios Pharmaceuticals, INC. | $20.94 | 2024 | |
| Adc Therapeutics America, INC. | $19.95 | 2022 | |
| Alnylam Pharmaceuticals INC. | $19.80 | 2025 | Givlaari |
| G1 Therapeutics, INC. | $17.31 | 2022 | |
| Caris Mpi, INC. | $15.69 | 2025 | Mi Cancer Seek |
| Sumitomo Pharma America, INC. | $15.13 | 2023 | Orgovyx |
| Global Blood Therapeutics, INC. | $15.10 | 2021 | |
| Pharmacyclics LLC, An Abbvie Company | $15.03 | 2022 | |
| Accord Healthcare, INC. | $14.94 | 2023 | |
| Tersera Therapeutics LLC | $11.86 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Natalee Neikirk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.